In order to test the presumed functions of the expanded CD133+ cells and their EVs, we conducted a preclinical study where we evaluated the effectiveness of the systemic application of the cells and their EVs for the treatment of ischemic cardiomyopathy in a rat model of AMI. The gene discussed is PROM1; the disease is ischemic cardiomyopathy.